Travere Licenses Civorebrutinib From Everest Medicines in Deal Worth Up to $1.14 Billion

June 9, 2026

Bristol Myers Squibb’s multiple sclerosis drug Zeposia gets FDA approval for ulcerative colitis

June 11, 2021

FDA delays approval of Duchenne gene therapy

May 25, 2023

Must Read

Claryx Appears From Stealth to Deal with the $45B Hospital-Acquired Infections Issue

August 5, 2026

Merck’s Tulisokibart Misses Phase 2 Endpoint in SSc-ILD but Meets Goals in HS Trial

August 5, 2026

The New Competitive Advantage in Biopharma Isn’t Science Alone

August 5, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Biogen’s Phase 2 Diranersen Data Shows Reduced Cognitive Decline in Alzheimer’s Disease

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Merck’s Tulisokibart Misses Phase 2 Endpoint in SSc-ILD but Meets Goals in HS Trial

After phase 3 data ended blockbuster hopes, GSK eliminated a major cough medication candidate

Hansoh Announces Fresh Phase 3 Victory For Priority ADC

Altimmune Reports Phase 2 Pemvidutide Results in Alcohol Use Disorder

Dimerix Acquires Phase 2-Ready AKI Drug DMX-652 From Mission Therapeutics

Lilly challenges J&J in the market for psychedelic mental health by paying $2.8 billion up front for AtaiBeckley

GSK will increase its R&D efforts by investing £400 million in Britain over three years

Claryx Appears From Stealth to Deal with the $45B Hospital-Acquired Infections Issue

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

The New Competitive Advantage in Biopharma Isn’t Science Alone

Why Protocol Complexity Continues to Threaten Trial Success

Top 10 Strategic Priorities for Pharmaceutical Leaders in 2026

Why Data Quality Is Becoming Pharma’s Biggest AI Challenge

Editorial Team

Potentially tough road for BMS as immuno-oncology pricing war looms

Editor Picks

Travere Licenses Civorebrutinib From Everest Medicines in Deal Worth Up to $1.14 Billion

Bristol Myers Squibb’s multiple sclerosis drug Zeposia gets FDA approval for ulcerative colitis

FDA delays approval of Duchenne gene therapy

Must Read

Claryx Appears From Stealth to Deal with the $45B Hospital-Acquired Infections Issue

Merck’s Tulisokibart Misses Phase 2 Endpoint in SSc-ILD but Meets Goals in HS Trial

The New Competitive Advantage in Biopharma Isn’t Science Alone

Hot Topics

About Us

Follow Us